MARKET

ATHE

ATHE

Alterity Therapeutics Ltd
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.480
0.000
0.00%
After Hours: 1.460 -0.02 -1.35% 18:37 12/04 EST
OPEN
1.450
PREV CLOSE
1.480
HIGH
1.530
LOW
1.440
VOLUME
276.12K
TURNOVER
--
52 WEEK HIGH
5.15
52 WEEK LOW
0.2800
MARKET CAP
25.59M
P/E (TTM)
-2.3775
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Zoom Video Communications, CureVac leads premarket losers' pack
Titan Pharmaceuticals (TTNP) -15%.Tuniu (TOUR) -15% on Q3 earnings release.Medigus (MDGS) -15% on appointment of new finance chief at MedigusECMOHO (MOHO) -14% on Q3 earnings release.Minerva Neurosciences (NERV) -14% after announcing outcome of Type C meeting with
Seekingalpha · 4d ago
The November Market Grinds Along
While it may not be my worst month this year, November may end up being the choppiest month for day trading I’ve traded so far in 2020.
Benzinga · 11/23 17:19
ATHE, MFGP, FCEL and PAYS among midday movers
Gainers: Phoenix Tree (DNK) +91%.Naked Brand (NAKD) +64%.Kazia Therapeutics (KZIA) +32%.Micro Focus International (MFGP) +32%.BELLUS Health (BLU) +31%.InnSuites Hospitality Trust (IHT) +27%.FuelCell Energy (FCEL) +27%.Ashford Hospitality Trust (AHT) +24%.CIIG Merger (CIIC) +23%.Kodiak Sciences (KOD)
Seekingalpha · 11/18 17:44
Lowe's Companies, GoodRx Holdings leads premarket losers' pack
Oncternal Therapeutics (ONCT) -26% after raising 'bought deal' offering to $22.5M.PaySign (PAYS) -25% on Q3 earnings release.Interpace Biosciences (IDXG) -17%.New Concept Energy (GBR) -12%.Alterity Therapeutics (ATHE) -11%.Yunhong CTI (CTIB) -8%.Lowe's Companies (LOW)-6% on Q3 earnings
Seekingalpha · 11/18 13:30
KNDI, RIOT, IBIO and GDRX among midday movers
Gainers: Phoenix Tree (DNK) +65%.Lexicon Pharmaceuticals (LXRX) +43%.Riot Blockchain (RIOT) +40%.Zomedica Pharmaceuticals (ZOM) +33%.Miragen Therapeutics (MGEN) +28%.AXT (AXTI) +27%.Glory Star New Media Group (GSMG) +26%.Yunhong CTI (CTIB) +23%.Kandi Technologies (KNDI) +22%.Sequential Brands (SQBG)
Seekingalpha · 11/17 17:44
Lexicon Pharmaceuticals, Zomedica Pharmaceuticals leads healthcare gainers; Brainstorm Cell Therapeutics, GoodRx Holdings among losers
Gainers: Lexicon Pharmaceuticals (LXRX) +45%, Zomedica Pharmaceuticals (ZOM) +33%, Miragen Therapeutics (MGEN) +17%, SQZ Biotechnologies (SQZ) +15%, PLx Pharma (PLXP) +13%.Losers: Brainstorm Cell Therapeutics (BCLI) -67%, GoodRx Holdings (GDRX) -19%, iBio (IBIO) -18%, Co-Diagnostics (CODX) -17%, Alterity Therapeutics (ATHE) -16%.
Seekingalpha · 11/17 16:06
Mid-Morning Market Update: Markets Open Lower; Walmart Beats Q3 Views
Following the market opening Tuesday, the Dow traded down 1.04% to 29,638.70 while the NASDAQ fell 0.27% to 11,892.15. The S&P also fell, dropping 0.73% to 3,600.40.
Benzinga · 11/17 15:38
CVS Health, Walgreens Boots Alliance among major healthcare premarket losers' pack
Brainstorm Cell Therapeutics (BCLI) -69% after announcing topline results from Phase 3 trial evaluating NurOwn.Alterity Therapeutics (ATHE) -24%.iBio (IBIO) -20% on FQ1 earnings release.The Alkaline Water Company (WTER) -17% on FQ2 earnings release.GoodRx Holdings (GDRX) -18% tumble after
Seekingalpha · 11/17 14:01
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATHE. Analyze the recent business situations of Alterity Therapeutics Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATHE stock price target is 4.000 with a high estimate of 4.000 and a low estimate of 4.000.
EPS
Institutional Holdings
Institutions: 21
Institutional Holdings: 641.13K
% Owned: 3.71%
Shares Outstanding: 17.29M
TypeInstitutionsShares
Increased
1
20.48K
New
7
130.71K
Decreased
1
52.88K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Chief Executive Officer/Director
Geoffrey Kempler
Chief Financial Officer
Kathryn Andrews
Senior Vice President
David Stamler
Secretary
Phillip Hains
Non-Executive Director
Tristan Edwards
Non-Executive Director
Lawrence Gozlan
Non-Executive Director
David Sinclair
Non-Executive Independent Director
Peter Marks
Non-Executive Independent Director
Brian Meltzer
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATHE
Alterity Therapeutics Limited, formerly Prana Biotechnology Limited, is a development-stage medical biotechnology company. The Company is engaged in the research and development of therapeutic drugs designed to treat the underlying cause of degeneration of the brain focusing on Alzheimer's disease, Huntington disease, Parkinson's disease and other neurological disorders. The Company's lead product candidates are PBT2 and PBT434. The Company's lead drug candidate PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. The Company also has advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in pre-clinical toxicology testing. Its other applications for its therapies include certain cancers, age-related macular degeneration, Motor Neuron disease, Creutzfeldt-Jakob disease (the human variant of Mad Cow disease), and a range of orphan neurodegenerative disorders.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Alterity Therapeutics Ltd (ADR) stock information, including NASDAQ:ATHE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATHE stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATHE stock methods without spending real money on the virtual paper trading platform.